Compare Sol-Gel Technologies Ltd. with Similar Stocks
Dashboard
1
Poor Management Efficiency with a low ROE of 0.67%
- The company has been able to generate a Return on Equity (avg) of 0.67% signifying low profitability per unit of shareholders funds
2
Poor long term growth as Net Sales has grown by an annual rate of 12.38% over the last 5 years
3
Positive results in Jun 25
4
Risky - Negative EBITDA
5
Consistent Returns over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
USD 176 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.78
-34.52%
6.74
Revenue and Profits:
Net Sales:
17 Million
(Quarterly Results - Jun 2025)
Net Profit:
12 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
10866.1%
0%
10866.1%
6 Months
12586.27%
0%
12586.27%
1 Year
8302.6%
0%
8302.6%
2 Years
1831.34%
0%
1831.34%
3 Years
1050.98%
0%
1050.98%
4 Years
470.55%
0%
470.55%
5 Years
701.73%
0%
701.73%
Sol-Gel Technologies Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
12.38%
EBIT Growth (5y)
12.94%
EBIT to Interest (avg)
-17.36
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.82
Sales to Capital Employed (avg)
0.31
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
33.85%
ROCE (avg)
0.98%
ROE (avg)
0.67%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.00
EV to EBIT
-0.26
EV to EBITDA
-0.26
EV to Capital Employed
1.00
EV to Sales
0.30
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-388.12%
ROE (Latest)
-64.66%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 2 Schemes (0.12%)
Foreign Institutions
Held by 8 Foreign Institutions (16.54%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
17.30
1.00
1,630.00%
Operating Profit (PBDIT) excl Other Income
11.20
-9.10
223.08%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
11.60
-8.80
231.82%
Operating Profit Margin (Excl OI)
650.60%
-8,796.30%
944.69%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 1,630.00% vs 233.33% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 231.82% vs -51.72% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
11.50
1.60
618.75%
Operating Profit (PBDIT) excl Other Income
-11.80
-29.00
59.31%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-10.60
-27.20
61.03%
Operating Profit Margin (Excl OI)
-1,041.30%
-18,893.20%
1,785.19%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 618.75% vs -58.97% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 61.03% vs -82.55% in Dec 2023
About Sol-Gel Technologies Ltd. 
Sol-Gel Technologies Ltd.
Pharmaceuticals & Biotechnology
Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.
Company Coordinates 
Company Details
Weizmann Science Park, 7, Golda Me'ir , NESS-ZIONA None : 7403650
Registrar Details






